An observational study in Adult Growth Hormone Deficiency, sponsored by Novo Nordisk A/S. Active, not recruiting at 47 sites in Japan. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Novo Nordisk A/S · Observational
Participants are invited to take part in this study because they have AGHD (only severe case). The purpose of this study is to assess long term safety and effectiveness of Sogroya® in patients with AGHD (only severe case) under normal clinical practice condition in Japan. Participants will get Sogroya® as prescribed by the study doctor. Participants will be in the study for about 2 to 5 years depending on when they take part in the study. Participants will be asked to fill in the quality of life questionnaires.
164 studies on the registry are indexed under Dwarfism, Pituitary; 25 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 37 observational studies indexed under Dwarfism, Pituitary.
Browse Dwarfism, Pituitary studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with Adult Growth Hormone Deficiency (only severe case)
Exclusion Criteria:
Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.
Drug: Somapacitan
Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
Also known as: Sogroya®
Number of adverse events
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Number of serious adverse events
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Number of serious adverse reactions
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Number of adverse reactions
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in body fat mass
Measured as kilogram (kg)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in body fat percentage
Measured as percent (%)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in lean body mass
Measured as kg
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in cross-sectional total adipose tissue compartments (TAT)
Measured as square centimeter (cm\^2)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in subcutaneous adipose tissue compartments (SAT)
Measured as cm\^2
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in visceral adipose tissue compartments (VAT)
Measured as cm\^2
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Total cholesterol (T-Cho)
Measured as milligrams per deciliter (mg/dL)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Low Density Lipoprotein-Cholesterol (LDL-Cho)
Measured as mg/dL
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in High Density Lipoprotein-Cholesterol (HDL-Cho)
Measured as mg/dL
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in triglyceride
Measured as mg/dL
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Insulin-like Growth Factor I (IGF-I) standard deviation score (SDS)
Measured as standard deviation score
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Quality of Life (QOL) Adult Hypopituitarism Questionnaire (AHQ) score
Measured as score range (0 = unfavorable to 6 = favorable)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in QOL Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) score
Measured as score range (1 to 5; lower score indicates a better health state)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S